ProCE Banner Activity

Statins in HIV? Applying the Results of the REPRIEVE Trial to My Patients Living With HIV in Mexico

Clinical Thought

Although the REPRIEVE trial showed benefit in decreasing cardiovascular events in persons living with HIV with low cardiovascular risk, to me, questions remain about the benefit of prescribing a statin to this population.

Released: August 17, 2023

Share

Faculty

Brenda E. Crabtree Ramírez

Brenda E. Crabtree Ramírez, MD

Assistant Professor, HIV Program
Department of Infectious Diseases
Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán
Mexico City, Mexico

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc., Janssen Therapeutics, Division of Janssen Products, LP, ViiV Healthcare

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

ViiV Healthcare

Partners

IAS 2023

ProCE Banner

Produced in collaboration with The International AIDS Society (IAS).

Faculty Disclosure

Primary Author

Brenda E. Crabtree Ramírez, MD

Assistant Professor, HIV Program
Department of Infectious Diseases
Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán
Mexico City, Mexico

Brenda E. Crabtree Ramírez, MD: researcher: Janssen, MSD, ViiV.